The most recent study, posted in January of 2018, suggest that previous claims about CBD and Parkinson’s to be probable. The endocannabinoid system has shown to play a huge role in neuropathological basis of Parkinson’s Disease. The study focuses specifically on the interactions of CB1 receptors, CB2 receptors and monoacylglycerol lipase (MAGL) gene expression. The study shows that these are closely related to neuropathological process of Parkinson’s Disease. Therefore, realizing the possible benefit of CBD as a potential therapeutic tool for those who are suffering while living with the side effects of Parkinson’s.
Research into the effects of cannabinoids, including cannabidiol, continues to progress into exploring an astonishing variety of systems and disorders. Although government restrictions on cannabis research hindered advancement until very recently, currently research has been blooming. If you would like to take part in this research and further our understanding of the biological mechanisms underlying the relief provided by the endocannabinoid system - check out the current clinical trials involving CBD. Many are currently recruiting participants all across the country - you could get involved!